10月7日,嘉和生物与亿腾医药双方宣布达成合并协议,这标志着两家企业将开启新的发展历程。嘉和生物和亿腾医药合并后的新公司将更名为"亿腾嘉和医药集团有限公司",合并后原亿腾医药股东将占比77.43%,成为新公司的实际控制人。
嘉和生物是一家致力于创新药物研发的生物制药公司,旗下重磅产品GB491(盐酸来罗西利片)已申请上市获得受理,有望成为中国首款上市的CDK4/6抑制剂。但嘉和生物目前缺乏商业化和营销能力,一直存在发展瓶颈。而亿腾医药拥有先进的制造平台、行业领先的营销网络,以及一些已上市产品并保持较好销售。
此次合并协议达成,双方将实现优势互补。通过整合资源,嘉和生物将借助亿腾医药的商业化能力来推进GB491等候选药物的商业化进程;亿腾医药则可以借助嘉和生物的创新管线进一步丰富产品线,同时获得包括高瓴、淡马锡等一批顶级投资机构作为投资人,增强了资金实力。业内人士认为,合并后双方有望形成协同效应,为长远发展奠定良好基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.